Current and historical daily PE Ratio for Livzon Pharmaceutical Group Inc (
) from 1993 to May 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Livzon Pharmaceutical Group stock (SZSE:000513) PE ratio as of May 21 2024 is 17.98.
More Details
Livzon Pharmaceutical Group Inc (SZSE:000513) PE Ratio (TTM) Chart
Livzon Pharmaceutical Group Inc (SZSE:000513) PE Ratio (TTM) Historical Data
View and export this data going back to 1993. Start your Free Trial
Total 1188
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Livzon Pharmaceutical Group PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-22 | 18.0 | 2024-03-13 | 18.3 |
| 2024-05-21 | 18.1 | 2024-03-12 | 18.5 |
| 2024-05-20 | 18.5 | 2024-03-11 | 18.6 |
| 2024-05-17 | 18.4 | 2024-03-08 | 18.6 |
| 2024-05-16 | 18.6 | 2024-03-07 | 18.4 |
| 2024-05-15 | 18.9 | 2024-03-06 | 18.9 |
| 2024-05-14 | 19.1 | 2024-03-05 | 18.9 |
| 2024-05-13 | 19.2 | 2024-03-04 | 19.0 |
| 2024-05-10 | 19.1 | 2024-03-01 | 18.3 |
| 2024-05-09 | 19.1 | 2024-02-29 | 18.3 |
| 2024-05-08 | 19.0 | 2024-02-28 | 17.8 |
| 2024-05-07 | 19.0 | 2024-02-27 | 17.9 |
| 2024-05-06 | 19.0 | 2024-02-26 | 17.8 |
| 2024-04-30 | 18.8 | 2024-02-23 | 17.9 |
| 2024-04-29 | 18.5 | 2024-02-22 | 18.1 |
| 2024-04-26 | 18.3 | 2024-02-21 | 17.9 |
| 2024-04-25 | 18.5 | 2024-02-20 | 18.1 |
| 2024-04-24 | 17.9 | 2024-02-19 | 17.7 |
| 2024-04-23 | 17.5 | 2024-02-08 | 17.6 |
| 2024-04-22 | 17.6 | 2024-02-07 | 18.1 |
| 2024-04-19 | 17.8 | 2024-02-06 | 17.7 |
| 2024-04-18 | 17.7 | 2024-02-05 | 16.5 |
| 2024-04-17 | 17.8 | 2024-02-02 | 15.9 |
| 2024-04-16 | 17.7 | 2024-02-01 | 16.0 |
| 2024-04-15 | 18.0 | 2024-01-31 | 16.1 |
| 2024-04-12 | 17.3 | 2024-01-30 | 16.4 |
| 2024-04-11 | 17.4 | 2024-01-29 | 16.8 |
| 2024-04-10 | 17.1 | 2024-01-26 | 16.6 |
| 2024-04-09 | 17.4 | 2024-01-25 | 16.8 |
| 2024-04-08 | 17.4 | 2024-01-24 | 16.6 |
| 2024-04-03 | 17.5 | 2024-01-23 | 16.3 |
| 2024-04-02 | 17.4 | 2024-01-22 | 16.2 |
| 2024-04-01 | 17.3 | 2024-01-19 | 17.0 |
| 2024-03-29 | 17.1 | 2024-01-18 | 17.1 |
| 2024-03-28 | 17.6 | 2024-01-17 | 17.2 |
| 2024-03-27 | 17.9 | 2024-01-16 | 17.3 |
| 2024-03-26 | 17.7 | 2024-01-15 | 17.2 |
| 2024-03-25 | 17.8 | 2024-01-12 | 16.9 |
| 2024-03-22 | 17.9 | 2024-01-11 | 16.8 |
| 2024-03-21 | 18.1 | 2024-01-10 | 16.7 |
| 2024-03-20 | 18.1 | 2024-01-09 | 16.8 |
| 2024-03-19 | 18.2 | 2024-01-08 | 16.8 |
| 2024-03-18 | 18.4 | 2024-01-05 | 16.9 |
| 2024-03-15 | 18.3 | 2024-01-04 | 17.2 |
| 2024-03-14 | 18.1 | 2024-01-03 | 17.1 |
Livzon Pharmaceutical Group Inc (SZSE:000513) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Livzon Pharmaceutical Group Inc
NAICS : 325412
ISIN : CNE0000002Y8
Share Class Description:
SZSE:000513: Class ACompare
Compare
Traded in other countries / regions
000513.China01513.Hong KongLP6.GermanyLVZPF.USA IPO Date
1993-10-28Description
Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment in PRC which is pharmaceutical manufacturing.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers